Trailing-twelve-month (TTM) revenue is $12.62 Billion with a year-over-year growth of +10.56%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $3,076,400,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $3,227,100,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-13 |
| Q1 FY2026Period ended 2026-03-31 | $2,986,900,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $3,333,900,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $12,624,300,000 |
Current P/S: $132,262,861,600 market capitalization ÷ $12,624,300,000 TTM revenue = 10.48x.
Market capitalization source: FMP quote. Quote observed 2026-09-09T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $3.33B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-09T20:00:00.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| ALYFTREK | N/A | N/A | N/A | N/A | N/A | $838M |
| KALYDECO | $803M | $684M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Europe | $1.1B | $2.0B | $2.7B | $3.1B | $3.5B | $3.5B |
| Non-US | N/A | N/A | N/A |
$12.62B
$12.62 Billion
+10.56%
vs. $11.42B a year ago (TTM)
+13.57%
5 Year compound annual growth rate
1 Year
+10.56%
3 Year
+9.92%
5 Year
+13.57%
10 Year
+23.28%
15 Year
+28.98%
20 Year
+24.08%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $12.07B | +$1.05B | +9.57% |
| 2024 | $11.02B | +$1.15B | +11.66% |
| 2023 | $9.87B | +$938.50M | +10.51% |
| 2022 | $8.93B | +$1.36B | +17.91% |
| 2021 | $7.57B | +$1.37B | +22.06% |
| 2020 |
TTM Growth
+10.56%
3-Year CAGR
+9.92%
5-Year CAGR
+13.57%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-09T20:00:00.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $476M |
| N/A |
| N/A |
| Manufactured Product, Other | N/A | N/A | N/A | N/A | $782M | $820M |
|---|
| ORKAMBI | $908M | $772M | $511M | $326M | N/A | N/A |
|---|
| SYMDEKO/SYMKEVI | $629M | $420M | $180M | $123M | N/A | N/A |
|---|
| TRIKAFTA/KAFTRIO | $3.9B | $5.7B | $7.7B | $8.9B | $10.2B | $10.3B |
|---|
| N/A |
| $5.4B |
| Other, Non U.S. | $250M | $313M | $526M | $720M | $881M | N/A |
|---|
| UNITED STATES | $4.8B | $5.3B | $5.7B | $6.0B | $6.7B | $7.5B |
|---|
| $6.21B |
| +$2.04B |
| +49.07% |
| 2019 | $4.16B | +$1.12B | +36.59% |
| 2018 | $3.05B | +$558.95M | +22.46% |
| 2017 | $2.49B | +$786.48M | +46.20% |
| 2016 | $1.70B | +$669.84M | +64.89% |
